Weekly docetaxel as second-line (palliative) chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma (SCCHN)

6067 Background: Relapse or distant metastases of squamous cell carcinoma of the head and neck (SCCHN) is considered to have poor prognosis with survival time of less than one year. Presently, ther...